Provided By GlobeNewswire
Last update: Jun 10, 2025
BROOMFIELD, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of UHealth — University of Miami Health System and the University of Miami Miler School of Medicine as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial site. The landmark CLARITY study is designed to demonstrate Nociscan’s clinical and economic value in spine surgery.
Read more at globenewswire.com7.33
-0.02 (-0.27%)
NASDAQ:ACONW (6/18/2025, 8:00:00 PM)
0.0338
+0.01 (+18.6%)
Find more stocks in the Stock Screener